phototechno Abeona Therapeutics (NASDAQ:ABEO) traded higher on Thursday after the company announced a partnership with eye care drug developer Beacon to evaluate its patented technology, AAV204, for gene therapies. Per the terms, Beacon, which belongs to Syncona’s clinical portfolio of companies, will have a non-exclusive right to evaluate AAV204 capsidContinue Reading
Tonpor Kasa Kazia Therapeutics (NASDAQ:KZIA) stock soared 142% in morning trading Wednesday after the company reported positive Phase 2/3 results for its drug paxalisib in the treatment of glioblastoma. A primary analysis of the study, called GBM-AGILE, showed a median overall survival of 14.77 months for paxalisib treated patients versusContinue Reading
Biopharmaceutical company Innovent Biologics (OTCPK:IVBIY) and IASO Biotechnology enter agreement under which IASO will purchase Innovent’s (OTCPK:IVBIY) relevant rights of FUCASO under the original “BCMA CAR-T Cell Therapy Cooperation Agreement” at the agreed price and Innovent (OTCPK:IVBIY) will use the proceeds to acquire an 18% stake in IASO Bio. UnderContinue Reading
Genezen said it will acquire uniQure’s (NASDAQ:QURE) commercial gene therapy operations in Lexington. Under the agreement, Genezen will enter into strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX product. The deal will be partly funded by additional growth equity from Ampersand Capital Partners.Continue Reading
Sviatlana Zyhmantovich Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ticker symbol “ARTV.” The San Diego, California-based biotech previously filed for a $100M IPO in 2021 to listContinue Reading
JHVEPhoto The U.S. Food and Drug Administration (FDA) has declined to approve an antibody-drug conjugate known as HER3-DXd developed by Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSKYF) as a late-line option for a certain type of lung cancer. The companies announced Thursday night that the agency issued a so-called complete responseContinue Reading
Genmab (GMAB) and partner AbbVie (NYSE:ABBV) have received U.S. FDA approval for their monoclonal antibody Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma. The approval is based on results from Phase 1/2 EPCORE NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients withContinue Reading
phototechno Consumer healthcare company Haleon (NYSE:HLN) announced an agreement on Wednesday to sell its nicotine replacement therapy (NRT) business outside the U.S. to a subsidiary of the Indian drugmaker Dr. Reddy’s Laboratories (NYSE:RDY). Per the terms, Dr. Reddy’s Laboratories SA, a unit of Dr. Reddy’s (RDY), will buy Haleon’s (HLN)Continue Reading
Md Saiful Islam Khan/iStock via Getty Images Annexon (NASDAQ:ANNX) shares traded higher on Wednesday after the company released additional data from its completed pivotal Phase 3 trial for its lead asset, ANX005, against the neurological disorder Guillain-Barré syndrome (GBS). Early this month, citing topline results from the study, the Brisbane,Continue Reading
CR Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO), which already have blockbusters with their weight loss drugs Zepbound (tirzepatide) and Wegovy (tirzepatide), are likely to dominate the market even if other drugs are approved, according to two Street analysts. Holly Morris, managing director at J.P. Morgan Asset Management focused onContinue Reading
